<DOC>
	<DOCNO>NCT00074750</DOCNO>
	<brief_summary>DTGM belong new generation drug design target leukemic cell . To achieve , DTGM take advantage ability naturally-produced growth factor ( GM , granulocyte-macrophage stimulating factor ) deliver drug ( diphtheria toxin ) cell ; preferably leukemic cell . It attach cell allow toxin enter leukemic cell destroy .</brief_summary>
	<brief_title>Study DT388GMCSF Fusion Protein Acute Myelogenous Leukemia ( AML ) Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description>The majority malignant myeloid progenitor cell express receptor GM-CSF . The fusion GM-CSF diphtheria toxin allow target cell GM-CSF receptor effect toxin spar GM-CSF receptor-lacking multipotent stem cell . The great majority AML cell express GM-CSF receptor DT388GMCSF show selective kill AML CMML progenitor vitro spar normal progenitor cell . When administer single bolus rodent , adequate blood DT388GMCSF biological activity find kill several log leukemic cell . A phase I clinical trial DT388GMCSF give daily bolus i.v . infusion 5 consecutive day complete 38 patient . The study define liver toxicity DLT . The liver toxicity observe patient &gt; 50 year receive steroid . Responses see four patient consist one complete remission 3 partial remission short duration . Peak drug level inversely proportional pre-treatment DT388GMCSF antibody level . Because observed significant preclinical activity AML CMML , clinical activity chemorefractory patient AML , association toxicity steroid exposure , association drug level antibody titer could decrease DT388GMCSF exposure , current follow phase I trial design base new administration dose - find trial also aim good determine control side effect , improve drug pharmacokinetics provide initial insight antileukemic activity novel agent , deliver prolonged intermittent schedule .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients refractory relapse AML ( marrow blast &gt; 20 % ) , must fail induction therapy relapse CR duration &lt; 6 month follow induction therapy , untreated refractory salvage chemotherapy . Relapsed AML patient CR duration &gt; 6 month previously untreated patient refuse chemotherapy consider treatment higher priority also eligible . Patients chronic myelomonocytic leukemia ( CMML ) fail least one course chemo biological therapy ( include trial erythropoietin ) , patient relapse CMML . Previously untreated CMML patient HB &lt; = 12 g / dL , eligible protocol high priority wish receive chemotherapy . Patients must ECOG performance status &lt; 2 . Patients must WBC count &lt; 10,000/mL prior initiate treatment . The WBC count must stabilize level least three day leukopheresis hydroxyurea . Hydroxyurea must discontinue one day prior initiation DT388GMCSF treatment . Patients must creatinine &lt; 1.6 time ULN : bilirubin &lt; 1.6 time ULN ; SGPT &lt; 2.6 x ULN ; albumin &gt; 3 gm/dl ; adequate cardiac function ( EF &gt; 44 % ) , oxygen saturation &gt; 92 % without exogenous oxygen administer . Patients must willing treated M D Anderson Cancer Center . Women childbearing potential men must agree practice contraception use approve method . No chemotherapy except Hydroxyurea 2 week prior enter study recover previous toxicity . Patients must &gt; 17 year old . Patients serious concurrent medical problem . Patients proven bacterial infection eligible resolution infection ( patient afebrile complete antibacterial therapy , steroid ) . Patients active fungal infection eligible evidence response antifungal medication document fever exceed 38C least 2 day . Inability give inform consent psychiatric problem serious medical problem . Pregnant nursing woman . Patients document CNS leukemia leukemia CNS symptom . Patients myocardial infarction within past six month . Patients severe penicillin allergy ( anaphylaxis ) . Not fully recover toxic effect prior chemotherapy radiation therapy . Patients corticosteroid treatment medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>CMML</keyword>
</DOC>